195 related articles for article (PubMed ID: 12790787)
1. How to target estrogen receptor-negative breast cancer?
Rochefort H; Glondu M; Sahla ME; Platet N; Garcia M
Endocr Relat Cancer; 2003 Jun; 10(2):261-6. PubMed ID: 12790787
[TBL] [Abstract][Full Text] [Related]
2. [Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?].
Rochefort H
C R Seances Soc Biol Fil; 1998; 192(2):241-51. PubMed ID: 9841098
[TBL] [Abstract][Full Text] [Related]
3. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
Lazennec G; Katzenellenbogen BS
Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
Sunami E; Shinozaki M; Sim MS; Nguyen SL; Vu AT; Giuliano AE; Hoon DS
Breast Cancer Res; 2008; 10(3):R46. PubMed ID: 18485221
[TBL] [Abstract][Full Text] [Related]
5. Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
Nath N; Chattopadhyay M; Rodes DB; Nazarenko A; Kodela R; Kashfi K
Molecules; 2015 Jul; 20(7):12481-99. PubMed ID: 26184135
[TBL] [Abstract][Full Text] [Related]
6. Expression and regulation of Cyr61 in human breast cancer cell lines.
Tsai MS; Bogart DF; Li P; Mehmi I; Lupu R
Oncogene; 2002 Jan; 21(6):964-73. PubMed ID: 11840342
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptors: new perspectives in breast cancer management.
Petrangeli E; Lubrano C; Ortolani F; Ravenna L; Vacca A; Sciacchitano S; Frati L; Gulino A
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):327-31. PubMed ID: 8043496
[TBL] [Abstract][Full Text] [Related]
8. Hormonal regulation of cathepsin D following transfection of the estrogen or progesterone receptor into three sex steroid hormone resistant cancer cell lines.
Touitou I; Vignon F; Cavailles V; Rochefort H
J Steroid Biochem Mol Biol; 1991; 40(1-3):231-7. PubMed ID: 1958526
[TBL] [Abstract][Full Text] [Related]
9. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
[TBL] [Abstract][Full Text] [Related]
10. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
11. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
Sengupta S; Schiff R; Katzenellenbogen BS
Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
[TBL] [Abstract][Full Text] [Related]
12. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
Yang Z; Barnes CJ; Kumar R
Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
[TBL] [Abstract][Full Text] [Related]
14. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S
J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor.
Russell KS; Hung MC
Cancer Res; 1992 Dec; 52(23):6624-9. PubMed ID: 1358436
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
18. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines.
Vladusic EA; Hornby AE; Guerra-Vladusic FK; Lakins J; Lupu R
Oncol Rep; 2000; 7(1):157-67. PubMed ID: 10601611
[TBL] [Abstract][Full Text] [Related]
19. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
20. RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER‑negative breast cancer models.
Yadav B; Taurin S; Larsen L; Rosengren RJ
Int J Oncol; 2012 Nov; 41(5):1723-32. PubMed ID: 22971638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
